Stifel starts AnaptysBio at buy, cites upcoming catalysts

admin

Stifel starts AnaptysBio at buy, cites upcoming catalysts


monsitj

Stifel has initiated coverage of AnaptysBio (NASDAQ:ANAB) with a buy rating, stating it views the company as a “key player in the next wave of immune cell modulatory therapies.”

Stifel said its bullish rating is based on its belief that

SOURCE

Leave a Comment

SITE SITE SITE SITE SITE SITE SITE SITE SITE SITE SITE SITE SITE SITE SITE SITE SITE SITE SITE SITE